# Ledning Boehringer Ingelheim är ett familjeägt företag som leds av en styrelse med verkställande direktörer. | | | | --- | --- | | | ## Shashank Deshpande
Chairman of the Board of Managing Directors with responsibility for the Human Pharma Business Unit | \*1 April 1973 Diplom-Kaufmann (Masters’ degree in Business Administration), University of Hamburg, Hamburg, Germany ### Professional milestones 2024 Member of the Board of Managing Directors with responsibility for the Animal Health Business Unit 2022 - 2023 Country Managing Director, Japan 2020 - 2022 Head of Human Pharma, Japan 2019 - 2020 Head of Specialty Care, Japan 2017 - 2019 Head of Marketing, Japan 2014 - 2017 Head of Diabetes Marketing, Japan 2012 - 2014 Global Brand Team Leader (Ingelheim, Germany) 2002 - 2012 Various roles in US and Global Marketing at Sanofi, US 1999 - 2002 Strategy consultant at Cap Gemini, Germany | | | | --- | --- | | | ## Michael Schmelmer
Vice Chairman of the Board of Managing Directors with responsibility for Group Functions | \*17 June 1964 Master Degree in Aerospace Technologies and Mechanical Engineering, Master Degree in Industrial Engineering ### Professional milestones 2019 – 2024 Member of the Board of Managing Directors with responsibility for Finance and Group Functions, Boehringer Ingelheim 2018 – 2019 Member of the Board of Managing Directors with responsibility for Finance, Boehringer Ingelheim 2016 – 2018 Founder and Managing Director of BI X, the digital lab of Boehringer Ingelheim 2012 – 2017 CIO, Corporate Senior Vice President Information Technology, Boehringer Ingelheim 2006 – 2012 Corporate Vice President IT & CIO, Infineon AG 2003 – 2006 Vice President IT Business Transformation, Infineon AG 2000 – 2003 Vice President Logistics & Supply Chain Management IT Systems, Infineon AG 1999 – 2000 Senior Director of Supply Chain Management Competence Center IT, Infineon AG | | | | --- | --- | | | ## Dr Paola Casarosa
Member of the Board of Managing Directors with responsibility for the Innovation Unit | \*2 February 1974 PhD in Molecular Pharmacology, Vrije Universiteit Amsterdam, The Netherlands MSc in Medicinal Chemistry, Università di Torino, Italy ### Professional milestones 2020 – 2023 Global Head of Therapeutic Areas 2019 - 2020 Global Therapeutic Area Head CNS, Retinopathy and Emerging areas 2019 - Head of Research Site Biberach, Germany 2014 - 2018 Global Head of Business Development, Prescription Medicine 2013 - 2014 Head of Therapeutic Alliances and Strategic Partnerships 2010 - 2013 Global Head Business Development and Licensing for Respiratory 2004 - 2010 Various Research roles at Boehringer Ingelheim and Organon (MSD) | | | | --- | --- | | | ## Frank Hübler
Member of the Board of Managing Directors with responsibility for Finance | \* July 18, 1971 Master of Science degree in Business Administration from the Catholic University Eichstätt, Ingolstadt, Germany ### Professional milestones 2019 – present   Head of Corporate Finance, Accounting, Controlling & Tax 2017 – 2019   Head of Corporate Controlling 2015 – 2017   Project Leadership Boehringer Ingelheim CHC/ Sanofi Merial swap transaction 2013 – 2015   Head of Global Reporting & Planning 2011 – 2013   Head of Finance & Administration UK & Ireland, Bracknell, UK 2007 – 2011   Head of Controlling Regional Center Vienna, Vienna, Austria 2005 – 2007   Senior Manager Internal Auditing, Burlington, Canada | | | | --- | --- | | | ## Dr Armin Wiesler
Member of the Board of Managing Directors with responsibility for the Animal Health Business Unit | \*12 June 1974 Doctoral and Master of Science degrees in Economics from the Albert-Ludwigs University Freiburg, Germany ### Professional milestones 2021 – 2024     Country Managing Director & Head of Animal Health Southeast Asia, Korea, Australia and New Zealand, based in Singapore 2020                      Head of Animal Health, region Southeast Asia and Korea, based in Singapore 2016 – 2020     General Manager Boehringer Ingelheim & Head of Human Pharma, Thailand 2014 – 2016     Regional Business Manager U.S. and Canada, based in Ingelheim, Germany 2010 – 2014     Human Pharma marketing leadership roles in Ingelheim, Germany & Ridgefield, U.S. 2008 – 2010     Head of Corporate Strategy & PMO, Corporate Development, Ingelheim, Germany 2001 – 2007     McKinsey & Company, Germany ### References